NCT02844894

Brief Summary

This study investigates the effects of dexmedetomidine and esmolol given intravenously before intubation on sympathetic response caused by intubation itself. Half the patients will recevice dexmedetomidine and the other half will receive dexmedetomidine. Ischemia modified albumine levels will be measured

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jun 2016

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 22, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 26, 2016

Completed
6 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2016

Completed
Last Updated

July 26, 2016

Status Verified

July 1, 2016

Enrollment Period

2 months

First QC Date

July 22, 2016

Last Update Submit

July 25, 2016

Conditions

Keywords

intubation, ischemia modified albumine, dexmedetomidine, esmolol

Outcome Measures

Primary Outcomes (1)

  • ischemia modified albumine

    ischemia modified albumine levels will be measured as a response to intubation

    10 minutes after endotracheal intubation

Study Arms (3)

dexmedetomidine

EXPERIMENTAL

0.5 mcg/kg dexmedetomidine in 20 ml normal saline will be infused in 5 minutes before intubation

Drug: Dexmedetomidine

Esmolol

EXPERIMENTAL

0.5 mg/kg esmolol in 20 ml normal saline will be infused in 5 minutes before intubation

Drug: Esmolol

Placebo

PLACEBO COMPARATOR

20 ml normal saline infused in 5 minutes before intubation

Drug: Placebo

Interventions

dexmedetomidine
Esmolol

normal saline

Placebo

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing elective surgery under general anesthesia

You may not qualify if:

  • Patient refusal
  • Morbid obesity (BMI\>30)
  • Advanced systemic disease
  • Hypoalbumiemia
  • beta-blocker usage
  • Anticipated difficult ventilation and/or intubation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ufuk University Hospital

Ankara, 06520, Turkey (Türkiye)

RECRUITING

Related Publications (1)

  • Yallapragada SV, Vidadala KS, Vemuri NN, Shaik MS. Comparison of the efficacy of dexmedetomidine with that of esmolol in attenuating laryngoscopic and intubation response after rapid sequence induction. Anesth Essays Res. 2014 Sep-Dec;8(3):383-7. doi: 10.4103/0259-1162.143154.

MeSH Terms

Interventions

Dexmedetomidineesmolol

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Central Study Contacts

Perihan Ekmekçi, Ass Prof

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

July 22, 2016

First Posted

July 26, 2016

Study Start

June 1, 2016

Primary Completion

August 1, 2016

Study Completion

September 1, 2016

Last Updated

July 26, 2016

Record last verified: 2016-07

Data Sharing

IPD Sharing
Will not share

Locations